Haibo Shen ,
Xuan He
Lushan Branch, Medical Community of the First People's Hospital, Fuyang District, Hangzhou, Zhejiang, China;
For correspondence:- Haibo Shen
Email: shen967@sina.com
Accepted: 28 October 2022
Published: 30 November 2022
Citation:
Shen H, He X.
25-Hydroxyvitamin D: A potential marker of the incidence of osteoporosis and sarcopenia in diabetic mellitus patients. Trop J Pharm Res 2022; 21(11):2487-2492
doi:
10.4314/tjpr.v21i11.31
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To investigate the feasibility of using the 25-hydroxyvitamin D (25(OH)D) levels in assessing osteoporosis (OP) and sarcopenia in elderly patients with diabetes mellitus (DM).
Methods: One hundred and forty elderly patients with DM were allocated to DM (n = 40), OP (n = 50), and DM + OP (n = 50) groups. Their clinical data were collected, and muscle function assessed. The levels of fasting insulin, glycated hemoglobin (HbAlc), t-P1NP, and 25(OH)D were determined by chemiluminescent microparticle immunoassay, high-pressure liquid chromatography, electrochemical immunoassay, and liquid chromatography-tandem mass spectrometry, respectively.
Results: The 25(OH)D levels were lowest in DM + OP group, followed by the OP group, and highest in the DM group (p < 0.05). The DM + OP group showed significantly lower gait speed and grip strength than the OP and DM groups (p < 0.05). The diagnostic AUC of 25(OH)D for OP and sarcopenia were 0.9733 (95 % CI: 0.9274 - 1.000, p < 0.001) and 0.9866 (95 % CI: 0.9632 - 1.000, p < 0.001). Patients with sarcopenia had significantly lower 25(OH)D and t-PINP levels than patients without sarcopenia (p < 0.05). Logistic regression analysis revealed that the 25(OH)D level, duration of DM, and age were independent risk factors for sarcopenia (p < 0.05).
Conclusion: Patients with DM and OP exhibit increase in the incidence of sarcopenia. Serum 25(OH)D may be used as a potential marker for the incidence of OP and sarcopenia in DM patients.
Keywords: 25(OH)D, Elderly, Diabetic patients, Osteoporosis, Sarcopenia, Feasibility analysis